Nextech Invest Ltd. reported 16 positions worth $2.17B for the quarter ended Sep 30, 2026, up 3.0% on the prior quarter. It opened 2 new positions, added to 2, trimmed 1 and exited 1. Its largest holding is Revolution Medicines, Inc. at 71.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| ARVN Arvinas, Inc. | -1.12M | $17.12M | 0.812% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVMD Revolution Medicines, Inc. | Healthcare | 7.60M | $1.56B | 71.86% | 0 | 0.0% | Unchanged | 3.51% |
| 2 | PBLS Parabilis Medicines, Inc. | Healthcare | 4.66M | $150.57M | 6.94% | 0 | 0.0% | Unchanged | 3.82% |
| 3 | RLAY Relay Therapeutics, Inc. | Healthcare | 6.78M | $122.32M | 5.63% | 0 | 0.0% | Unchanged | 3.09% |
| 4 | ORIC Oric Pharmaceuticals, Inc. | Healthcare | 7.16M | $96.48M | 4.44% | 0 | 0.0% | Unchanged | 6.62% |
| 5 | TYRA Tyra Biosciences, Inc. | Healthcare | 3.45M | $75.40M | 3.47% | -106.1K | -3.0% | Reduced | 4.99% |
| 6 | ALMS Alumis Inc. | Healthcare | 4.55M | $33.63M | 1.55% | +1.01M | +28.5% | Added | 3.51% |
| 7 | KYMR Kymera Therapeutics, Inc. | Healthcare | 278.9K | $31.18M | 1.44% | 0 | 0.0% | Unchanged | 0.28% |
| 8 | ZYME Zymeworks Inc. | Healthcare | 1.11M | $29.51M | 1.36% | 0 | 0.0% | Unchanged | 1.56% |
| 9 | SLN Silence Therapeutics plc | Healthcare | 1.69M | $18.51M | 0.852% | +740.7K | +77.8% | Added | 2.72% |
| 10 | CTMX CytomX Therapeutics, Inc. | Healthcare | 4.45M | $12.10M | 0.557% | 0 | 0.0% | Unchanged | 2.03% |
| 11 | AVTX Avalo Therapeutics, Inc. | Healthcare | 766.0K | $11.74M | 0.541% | +766.0K | – | New | 1.39% |
| 12 | GLUE Monte Rosa Therapeutics, Inc. | Healthcare | 761.2K | $9.08M | 0.418% | 0 | 0.0% | Unchanged | 0.75% |
| 13 | BRVE Braveheart Bio, Inc. | Healthcare | 416.7K | $8.42M | 0.388% | +416.7K | – | New | 0.51% |
| 14 | CRVS Corvus Pharmaceuticals, Inc. | Healthcare | 450.0K | $5.18M | 0.239% | 0 | 0.0% | Unchanged | 0.49% |
| 15 | ENGN enGene Therapeutics Inc. | Healthcare | 2.32M | $4.65M | 0.214% | 0 | 0.0% | Unchanged | 3.33% |
Tip. Select a row to see that position’s full history at Nextech Invest.
As of its Q3 2026 13F filing, Nextech Invest Ltd.’s five largest positions were Revolution Medicines, Inc. (RVMD) at 71.9%, Parabilis Medicines, Inc. (PBLS) at 6.9%, Relay Therapeutics, Inc. (RLAY) at 5.6%, Oric Pharmaceuticals, Inc. (ORIC) at 4.4%, Tyra Biosciences, Inc. (TYRA) at 3.5% of the reported portfolio.
Nextech Invest Ltd. reported a 13F portfolio worth $2.17B across 16 positions for Q3 2026. That is up 3.0% from the previous quarter.
Its largest purchases by value were Avalo Therapeutics, Inc. ($11.74M), Braveheart Bio, Inc. ($8.42M), Silence Therapeutics plc ($8.10M). It opened 2 new positions.
Its largest sales by value were Arvinas, Inc. ($17.12M), Tyra Biosciences, Inc. ($2.32M). It exited 1 positions entirely.
From the Form 13F-HR reports Nextech Invest Ltd. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.